Overexpression of the Ron receptor tyrosine kinase has recently been shown in a wide variety of human cancers. However, no studies have examined Ron receptor expression or function during prostate tumorigenesis. In this study we report that Ron is highly expressed in human prostate adenocarcinoma and metastatic lymph nodes when compared with normal prostate or benign prostate hyperplasia. Furthermore, we show that Ron is overexpressed in PC-3 and DU145 prostate cancer cell lines, and that the levels of angiogenic chemokines produced by prostate cancer cells positively correlate with Ron expression. The knockdown of Ron in PC-3 or DU145 cells results in a significant decrease in angiogenic chemokine production and is associated with a decreased activation of the transcription factor nuclear factor-jB (NF-jB). Moreover, exogenous overexpression of Ron in LNCaP cells is sufficient to induce a significant increase in angiogenic chemokines that can be abrogated by inhibition of NF-jB signaling. Given that the function of angiogenic chemokines is important in the development of new blood vessels, we also examined the ability of Ron to modulate endothelial cell migration. Our data show that knockdown of Ron in prostate cancer cells results in significantly less endothelial cell chemotaxis when compared with Ron-expressing cells in vitro as well as in reduced tumor growth and decreased microvessel density after orthotopic transplantation into the prostate in vivo. In total, our data suggest that the Ron receptor is important in modulating prostate tumor growth by modulating angiogenic chemokine production and subsequent endothelial cell recruitment.
Introduction
Prostate cancer is the second leading cause of cancerrelated deaths among men, and one in six men will be diagnosed with this disease during his lifetime. Although current treatment modalities, such as a radical prostatectomy or radiation therapy, can prove to be beneficial in the short term for early-stage prostate cancer, recurrence is common. Once prostate cancer cells metastasize, the mortality rate dramatically increases (Pound et al., 1999) . Therefore, to more successfully treat prostate cancer, a greater understanding of the biological and physiological mechanisms that are involved in regulating prostate tumor growth and metastasis is needed.
Angiogenesis, the formation of new blood vessels from pre-existing vessels, is a critical factor in tumor growth and metastasis. This process provides the essential nutrients to nourish the growing tumor and is also important in removing waste products from the tumor. Moreover, studies have shown that prostate tumor angiogenesis positively correlates with increased tumor growth and progression and is associated with decreased mean survival time (Lissbrant et al., 1997) . Without prostate tumor angiogenesis, the tumor would not be able to grow and metastasize and, therefore, the factors involved in tumor angiogenesis are promising targets for prostate cancer therapeutics (Craft and Harris, 1994; Jimenez et al., 2006) .
One such potential target is the Ron receptor tyrosine kinase. Ron is the only other member of the Met family of cell surface receptors, and has been implicated in several human cancers (Maggiora et al., 1998; Chen et al., 2000; O'Toole et al., 2006; Thomas et al., 2007) . The Ron receptor is expressed preferentially in macrophages and epithelial cells (Leonis et al., 2007; Wagh et al., 2008) . The Ron ligand, hepatocyte growth factorlike protein (HGFL), is predominantly expressed in hepatocytes and is secreted into the circulation working primarily in an endocrine manner (Bezerra et al., 1993 (Bezerra et al., , 1998 . Binding of HGFL to Ron leads to receptor phosphorylation and activation, which then results in the regulation of a wide variety of downstream signaling pathways implemented in multiple cellular processes, including cellular proliferation, migration, branching morphogenesis and cell scattering (Leonis et al., 2007; Wagh et al., 2008) . Interestingly, we have shown previously that in a mouse model of breast cancer, mice deficient in Ron show reduced mammary tumor formation with a decrease in tumor microvessel density, suggesting that Ron has a role in tumor angiogenesis (Peace et al., 2005) . The role of the Ron receptor in prostate tumor growth and angiogenesis is, however, unknown.
Chemokines are a group of small molecules ranging in size from 8 to 10 kDa that are classified into four groups based on conserved cysteine residues near the amino terminus. Chemokines are important in several biological processes, including the inflammatory response, and also in certain diseases such as chronic inflammation and atherosclerosis. In addition, a family of chemokines called angiogenic chemokines have been shown to be important regulators of neovascularization. Angiogenic chemokines share conserved cysteine residues separated by any amino acid (CXC) followed by a glutamate-leucine-arginine (ELR þ ) motif near the amino terminus. The ELR motif is critical for the pro-angiogenic functions of these chemokines (Keeley et al., 2008) . CXC ELR þ chemokines, including CXCL1, CXCL5 and CXCL8, act as chemoattractants for endothelial cells. Conversely, angiostatic CXC chemokines such as CXCL10, which lack the ELR þ motif, act in an opposite manner (Rollins, 1997) . The balance between angiogenic and angiostatic chemokines that is present in normal cells becomes deregulated in highly proliferative cancer cells, resulting in increased angiogenic CXC chemokine production and subsequent increased tumor angiogenesis (Strieter et al., 2006) . Angiogenic chemokines, produced and secreted by prostate cancer cells, form a gradient and promote endothelial cell migration from existing blood vessels by binding to their receptor, CXCR2 (Shen and Lentsch, 2004) . This process results in the formation of new blood vessels from pre-existing vessels that integrate into the tumor (Waugh et al., 2008) . CXCL8, in particular, has been shown to be a strong inducer of endothelial cell migration through binding to the CXCR2 receptor (Shen et al., 2006; Waugh et al., 2008) .
Increased angiogenic chemokine production has been implicated in the pathogenesis of prostate cancer (Greene et al., 1997; Hepburn et al., 1997; Balbay et al., 1999) . When prostate cancer cells are injected into severe combined immunodeficient mice, tumor growth can be inhibited by blocking antibodies against CXCL1 and CXCL8, thus showing the significance of angiogenic chemokines in prostate tumor growth (Moore et al., 1999) . In addition, in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer, mice lacking the CXCR2 receptor have decreased prostate tumor size and decreased prostate tumor angiogenesis, further signifying the importance of angiogenesis in prostate tumor growth (Shen et al., 2006) . Interestingly, inhibiting the nuclear factor-kB (NF-kB) transcription factor in PC-3 prostate cancer cells results in decreased angiogenic chemokine production (Shen and Lentsch, 2004) , suggesting that NF-kB is a critical regulator of angiogenic chemokine production in these cells.
To analyse the significance of Ron in prostate cancer, we examined the expression and function of this receptor in relation to prostate tumor formation and angiogenesis. Our studies show that Ron is highly expressed in human prostate cancers and that Ron expression levels are associated with the production of angiogenic chemokines in prostate cancer cells. We also show that overexpression of Ron in LNCaP cells is sufficient to induce CXCL8 production and that this expression is dependent, at least in part, on NF-kB activation. Coordinately, Ron inhibition in PC-3 or DU145 cells results in a significant decrease in angiogenic chemokine production and a Ron knockdown in DU145 cells leads to decreased NF-kB activity. This regulation by Ron is biologically important in the regulation of endothelial cell migration and in vivo by effecting prostate tumor vascularization.
Results
Ron is overexpressed in human prostate cancer specimens Ron expression has been grossly examined in a variety of human cancers including prostate cancer, although there has been no published reports analysing relative Ron expression during prostate tumorigenesis (O'Toole et al., 2006; Wang et al., 2007) . To determine the degree of Ron overexpression throughout the progression of prostate disease, we analysed a series of human prostate tissue arrays for Ron expression using immunohistochemistry. Figure 1 shows representative Ron staining observed in normal prostate tissue, prostate adenocarcinoma and in metastatic prostate disease. Table 1 documents the percentage of Ron-positive tissues per category as well as the mean intensity of Ron expression observed. It is noteworthy that high Ron expression was observed in the benign prostate hyperplastic tissue when compared with normal prostate tissue, with an even further increase in Ron expression detected in prostate adenocarcinoma tissue. In addition, all three lymph nodes analysed with prostate metastases showed high Ron expression.
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Figure 1 Ron is highly expressed in human prostate cancer specimens. Increased Ron expression is observed in prostate cancer and metastatic tissue when compared with normal prostate tissue. Representative stained specimens of normal prostate, prostate adenocarcinoma and metastatic lymph node from advanced prostate cancer are depicted.
Ron is highly expressed in PC-3 and DU145 human prostate cancer cells
To determine the expression of Ron in human prostate cells, western blot analyses were performed. As shown in Figure 2a , western blot analysis shows high Ron expression in PC-3 and DU145 cells and little Ron expression in 22RV1 and LNCaP cells. Interestingly, PC-3 and DU145 cells are two androgen-independent prostate cancer cell lines derived from metastatic prostate cancers. Further analysis of Ron expression (Supplementary Figure S1A) shows that PC-3 cells express high amounts of Ron, whereas the non-invasive CA-HPV-10 cells derived from a primary human prostate tumor express an intermediate amount of Ron and the non-transformed, immortalized prostate cell line PZ-HPV-7 has very little Ron expression ( Table 2) . These results correlate with the pattern of Ron expression observed in the human prostate tumor tissue arrays shown in Figure 1 and Table 1 .
Ron is active in PC-3 and DU145 cells
In many tumors overexpressing Ron, a high degree of receptor phosphorylation is frequently observed (Maggiora et al., 1998; Peace et al., 2001; Zhou et al., 2003; Wang et al., 2007) . To determine whether Ron is phosphorylated and serves as an active kinase in prostate cancer cells, we performed western blot analyses after immunoprecipitation with a Ron-specific antibody. As shown in Figure 2b , Ron is tyrosine phosphorylated in PC-3 and DU145 cells, suggesting that Ron is active in these cell lines. We also analysed PZ-HPV-7 (a low Ron-expressing cell line) cells for tyrosine phosphorylation of Ron after Ron immunoprecipitation. Compared with PC-3 and DU145 cells, PZ-HPV-7 cells have minimal tyrosine phosphorylation of Ron (Figure 2b ). To further determine the activity of Ron, we performed kinase assays on Ron immunoprecipitated from PC-3 or DU145 cells. Using myelin basic protein as an exogenous substrate, we observed that both PC-3 and DU145 cells show Ron-dependent kinase activity ( Figure 2c ). Interestingly, similar results were observed with cells cultured in media containing serum and with cells under serum-deprivation conditions (data not shown). We have also shown that these prostate cancer cells do not endogenously produce the Ron ligand, HGFL (data not shown), suggesting that Ron may be constitutively phosphorylated and active in the absence of ligand in these prostate cancer cell lines.
Prostate cancer cells with high Ron expression also produce high levels of angiogenic chemokines
To determine whether prostate cancer cells with high Ron expression also produce relatively high levels of angiogenic chemokines, we analysed the prostate cancer cell lines, LNCaP, 22RV1, DU145 and PC-3, for the production of the angiogenic chemokines, CXCL8 (Figure 3a The percentage of human prostate specimens that stained positive for Ron expression and the mean intensity of Ron staining is shown. The number of Ron-expressing samples over the total number of samples examined is shown in parentheses. A lysate control is shown representing 20% of the total input. (c) DU145 or PC-3 cells were immunoprecipitated with a Ron antibody (or with immunoglobulin G (IgG) as a control), and a kinase assay was performed with myelin basic protein as substrate. Controls included reactions that did not include substrate.
of CXCL1 or CXCL5. To determine whether the changes in chemokine production did not simply reflect changes in cell growth among the various cell lines, the growth of all the cell lines was monitored over the time course of the experiment. As shown in Figure 3d , the change in cell growth over time was similar in LNCaP, 22RV1 and PC-3 cells, although the DU145 cells showed an increase in cell number by 72 h. Given this increase in cell number, the relative levels of chemokines from DU145 cells are shown, which have been normalized to cell number for Figures 3a-c. Similar to protein expression, LNCaP and 22RV1 cells had undetectable levels of CXCL8 ( Figure 3e ) and CXCL5 mRNA (Figure 3f ), although these cells had the highest levels of vascular endothelial growth factor (VEGF) mRNA ( Figure 3g ).
Ron inhibition in PC-3 or DU145 cells led to decreased production of angiogenic chemokines but not of VEGF or the angiostatic chemokine CXCL10
We have shown that Ron expression correlates with angiogenic chemokine production in prostate cancer The levels of CXCL8, CXCL1 and CXCL5 in prostate cancer cells. LNCaP, 22RV1, DU145 and PC-3 cells were placed in serum-free media for 72 h and supernatant was used to determine the levels of CXCL8 (a), CXCL1 (b) and CXCL5 (c) using enzyme-linked immunosorbent assay (ELISA). Only DU145 and PC-3, which overexpress Ron, produce CXCL8 and CXCL1 whereas a limited to no expression of these chemokines is observed in LNCaP and 22RV1 cells. Only PC-3 cells had detectable levels of CXCL5. Similar levels of all three chemokines were also observed at 96 h (data not shown). (d) DU145 cells grow at a greater rate than LNCaP, 22RV1 and PC-3 cells. At 72 h after plating cells, crystal violet assays were performed to determine changes in cell number over time. All LNCaP, 22RV1 and PC-3 cells had similar rates of cell growth over 72 h, whereas DU145 had a higher growth rate. The relative levels of chemokines in (a-c) reflects a normalization to cell number for the DU145 cells (see Materials and methods). (e-g) RNA levels of CXCL8, CXCL5 and vascular endothelial growth factor (VEGF) in prostate cancer cells. Similar to results determined using ELISA, quantitative real-time PCR analyses confirmed that both DU145 and PC-3 cells have high levels of CXCL8 (e), whereas PC-3 cells are the only cell line that had detectable levels of CXCL5 (f). Conversely, DU145 and PC-3 have low levels of VEGF compared with LNCaP and 22RV1 cells (g). cells, and next sought to determine the effect of Ron inhibition on chemokine production. PC-3 cells were transfected with either Ron-specific small interfering RNA (Ron siRNA) or non-specific scrambled siRNA (non siRNA). A significant loss of Ron mRNA was observed by 48 h after transfection (Figure 4a ). To examine whether loss of Ron expression affected chemokine production in these cells at 30 h after transfection, the cells were placed into serum-free media and supernatant was collected at specific intervals. During this time frame, there was no significant change in cell number between control PC-3 cells and Ron knockdown PC-3 ( Figure 4e ). There were significant decreases in the angiogenic chemokines CXCL8 (Figure 4b ), CXCL5 ( Figure 4c ) and CXCL1 (Figure 4d ) secreted by Ron-knockdown PC-3 cells when compared with control cells. The production of VEGF and the angiostatic chemokine CXCL10 were also examined. PC-3 cells secrete relatively low levels of these factors (VEGF, Figure 3g ) and there was no change in production in either CXCL10 or VEGF with Ron loss (data not shown). To complement our studies and to determine the specificity of Ron inhibition in another cell line, Ron expression was also knocked down in DU145 cells by infection with either a nonsense short hairpin RNA (shRNA) construct (shNon) as a control or a Ron shRNA construct (shRon). As shown in Figure 5a , Ron expression was efficiently depleted in the Ron shRNAinfected cells, which was associated with a significant decrease in CXCL8 production when compared with control infected cells (Figure 5b) . No change in cell proliferation was observed between DU145 control cells or DU145 Ron knockdown cells (Figure 5c ).
Ron inhibition blocks nuclear factor-kB (NF-kB) activity in DU145 cells
Nuclear factor-kB has been shown previously to be an important regulator of angiogenic chemokine produc- tion in prostate cancer cells (Shen and Lentsch, 2004; Wilson et al., 2008) . To examine whether Ron regulates angiogenic chemokine production by affecting NF-kB activation, we examined NF-kB activity in control (shNon) and Ron knockdown (shRon) DU145 cells. Cells were transfected with an NF-kB reporter construct and a control plasmid. After 24 h, cells were lysed and analysed for NF-kB activity using a dual-luciferase reporter assay system (Promega, Madison, WI, USA). Figure 5d shows a significant decrease in NF-kB reporter activity in the Ron knockdown DU145 cells compared with control cells, which is consistent with the decreased angiogenic chemokine production observed in Figure 5b . Consistent with the decrease in NK-kB activity, a corresponding increase in the NF-kB inhibitory protein, IkBa, was observed in the Ron knockdown DU145 cells when compared with the control cells (Figure 5a ). To further support modulations in NF-kB activity, electrophoretic mobility shift assays were performed as previously described (Shen and Lentsch, 2004; Nikolaidis et al., 2009) . Ron loss in DU145 cells led to a decrease in NF-kB (p65 and p50) DNA-binding activity (Supplementary Figure S2) .
Prostatic Ron expression is important to induce endothelial cell migration
We have shown that Ron is an important mediator of angiogenic chemokine production in prostate cancer cells. Next, we wanted to determine the functional effect of Ron signaling on the chemotactic migration of endothelial cells. Human umbilical vein endothelial cells (HUVECs), which were previously shown to express the CXCR2 receptor and respond to angiogenic chemokines, were used (Li et al., 2003) . Serum-free cell culture supernatant was collected from DU145 stable Ron knockdown (shRon) or control (shNon) cells. The culture supernatant was then applied as a chemoattractant for HUVECs in a transwell migration assay. Figure 5e shows that the loss of Ron in DU145 cells led to a significant reduction in endothelial cell migration. Previous studies have shown that endothelial cell migration to PC-3 cell culture supernatant can be partially blocked by inhibiting the angiogenic chemokine receptor, CXCR2, on the endothelial cells (Shen et al., 2006) . Similarly, endothelial cell migration to DU145 cell culture supernatant can also be significantly reduced by inhibition of CXCR2 (Supplementary Figure S2C ).
Ron overexpression is sufficient to induce CXCL8 production in LNCaP prostate cancer cells through a mechanism dependent on NF-kB signaling We have shown that Ron inhibition led to a diminution of angiogenic chemokine production by PC-3 and DU145 prostate cancer cell lines. To examine whether Ron overexpression in prostate cancer cells is sufficient to induce angiogenic chemokine production, Ron was stably overexpressed in LNCaP cells (Figure 6a ). In Ron-overexpressing LNCaP cells, we observed significantly increased CXCL8, both at the protein (Figure 6b ) and RNA (Figure 6c ) level when compared with control transfected cells. Moreover, this induction in CXCL8 is further enhanced when these cells are treated with the Ron ligand, HGFL (Figure 6b ). However, there was not a statistical difference between HGFL treated and untreated groups. Interestingly, Figure 6d shows that this induction of CXCL8 could be abrogated with the NF-kB pathway inhibitor Bay 11-7085. 
Ron expression promotes prostate tumor microvessel density
To examine a role for Ron in tumor vascularization in vivo, PC-3 cells with a stable knockdown of Ron (Figure 7a ) or control cells were orthotopically injected into the prostates of nude mice. At 7 weeks after injection, the prostates were harvested and prostate tumor mass ( Figure 7b ) and microvessel density was determined (Figures 7c and d) . Compared with control cells, Ron knockdown cells not only formed smaller tumors, but also the overall microvessel density per equal area of tumor was significantly less. Figure S3A ). Met levels are similar to the expression pattern of Ron in these cells (Figure 2a ). To determine whether a Ron knockdown in prostate cancer cells alters Met expression, we examined DU145 control cells or DU145 Ron knockdown cells for Met expression. Ron knockdown does not alter Met levels either at the RNA (Supplementary Figure S3B ) or protein level (Supplementary Figure S3C ).
Ron knockdown in DU145 cells does not affect Met expression To examine the relationship between Ron and Met in prostate cancer cells, real-time PCR analysis was performed for Met in PC-3, DU145, 22RV1 and LNCaP cells. PC-3 cells have the highest levels of Met, DU145 and 22RV1 cells have intermediate levels, and LNCaP cells have minimal Met expression (Supplementary
Discussion
Ron overexpression has been associated with several different human cancers, including prostate cancer (O'Toole et al., 2006) . Our studies show for the first time that Ron overexpression may have an important role in human prostate cancer progression by promoting the production of angiogenic chemokines. This regulation of angiogenic chemokines by Ron is functionally significant because the amount of chemokines produced and secreted affects endothelial cell migration. Given that the levels of angiogenic chemokines and extent of endothelial cell migration are critical steps in angiogenesis (Waugh et al., 2008) , our data suggest that the Ron receptor may be an important mediator of prostate tumor angiogenesis. In this report, we have shown that Ron expression is increased in human benign hyperplastic prostate tissue and is further increased in human prostate adenocarcinoma relative to normal prostate tissue ( Figure 1 and Table 1 ). Similar results were observed in human pancreatic tissue in which minimal Ron expression was detected in the normal pancreatic ducts or in early pancreatic intraepithelial neoplasia, although Ron was highly expressed in the more advanced pancreatic disease (Thomas et al., 2007) . This consistent expression pattern suggests that Ron may be having a role in the progression to advanced disease. Although with our limited sample size we did not find Ron expression to correlate with either prostate cancer grade or Gleason score, there are several gene expression array studies that show that Ron expression is progressively higher in metastatic prostate cancer when compared with prostate carcinoma, and that Ron in prostate carcinoma is more highly expressed than in the normal prostate (Dhanasekaran et al., 2005; Lapointe et al., 2007) . In addition, multiple studies have indicated that Ron overexpression, examined using microarray analyses, also correlates with hormone-refractory/androgen-independent prostate cancers (Best et al., 2005; Varambally et al., 2005; Tomlins et al., 2007) . These studies support our observations that Ron is highly expressed in prostate cancer adenocarcinoma and in metastatic prostate cancer, and minimally expressed in normal or benign prostate specimens.
An analysis of immortalized human prostate cell lines revealed a similar trend to that found in human prostate specimens, in which Ron expression increased from the non-transformed, immortalized cells (PZ-HPV-7) to cells derived from benign prostate tumor (CA-HPV-10) and metastatic prostate (PC-3 and DU145). Interestingly, the two androgen-independent prostate cancer cell lines, PC-3 and DU145, have high Ron expression, whereas 22RV1 and LNCaP express little-to-no Ron (Figure 2a and Table 2 ). Similar to Ron, the related receptor tyrosine kinase, Met, has recently been shown to be upregulated in prostate cancer (Verras et al., 2007) . Our analysis of Met expression in prostate cancer cell lines showed a similar trend to Ron expression (Supplementary Figure S3A) . Interestingly, androgen receptor signaling was shown to negatively regulate Met expression at the transcriptional level in androgendependent prostate cancer cells. In addition, LNCaP xenografts in castrated severe combined immunodeficient mice had upregulated Met expression as compared with intact mice, and Met expression levels were inversely correlated with androgen receptor expression (Verras et al., 2007) . These data suggest that Met signaling may have a role in androgen-independent prostate cancer. On the basis of the progressive increase in Ron expression observed in prostatic hyperplasia and prostate adenocarcinoma compared with normal prostate tissue, the high expression of Ron observed in the three metastatic lymph nodes analysed and an increased Ron expression in androgen-independent cell lines, it is interesting to speculate that the Ron receptor may also have an important role in androgen-independent prostate cancer.
On the basis of kinase assays and western blot analyses performed in serum-free and serum-containing conditions, our data suggest that Ron shows constitutive receptor phosphorylation and kinase activity in PC-3 and DU145 cells (Figures 2b and c) . Immunohistochemical staining of human tumor specimens and an analysis of tumor lysates from breast and colon tissues has shown that Ron overexpression is associated with a high degree of receptor phosphorylation (Maggiora et al., 1998; Zhou et al., 2003) . Our studies are also consistent with overexpression studies performed in NIH/3T3 cells in which the overexpression of Ron was sufficient to induce activity of this receptor (Peace et al., 2001) . Although we have observed constitutive Ron activity in cell lines after overexpression, the requirement of HGFL in Ron-expressing tumors in vivo has not yet been established. Interestingly, we have not observed endogenous expression of HGFL in any of the prostate cell lines used in this study, although in vivo, it is important to note that HGFL is available in the prostate microenvironment because of the high circulating levels of this protein and may provide a functional role in tumor promotion (Bezerra et al., 1993 (Bezerra et al., , 1998 . Consistent with this idea, a recent report has shown that exogenous overexpression of HGFL in Ron-expressing breast tumors led to increased tumor growth and a broadened pattern of metastatic dissemination, suggesting that HGFL is an important contributor to metastases (Welm et al., 2007) .
We show that Ron expression in prostate cell lines correlates with the expression levels of a select group of CXC ELR þ chemokines, in particular CXCL8, CXCL5 and CXCL1. The prostate cancer cell lines, PC-3 and DU145, which show the highest Ron expression, produce the highest levels of these angiogenic chemokines (Figure 3 ). We showed that PC-3 cells, which were transiently transfected with a Ron-specific siRNA, resulted in a significantly decreased production of CXCL8, CXCL5 and CXCL1 (Figure 4) . Further, the diminution of Ron expression was specific for this group of chemokines, as there were no alterations observed in the CXC ELRÀ chemokine CXCL10 or in the production of VEGF. Similarly, Ron inhibition in DU145 cells led to decreased CXCL8 (Figure 5b) , showing the regulation of chemokine production by Ron in multiple prostate cancer cell lines. In support of the significance of Ron expression in the induction of angiogenic chemokines, we showed that exogenous Ron expression in LNCaP cells was sufficient to induce the production of CXCL8 ( Figure 6 ). These studies are the first to implicate the Ron receptor tyrosine kinase in the production of angiogenic factors in epithelial cancer cells, and suggest that this receptor may have an important role in regulating tumor angiogenesis.
With respect to angiogenesis, previous studies have linked the significance of angiogenic chemokines with the migration and chemoattraction of endothelial cells and with angiogenesis in vivo (Koch et al., 1992; Hepburn et al., 1997; Balbay et al., 1999; Addison et al., 2000; Salcedo et al., 2000) . Importantly, we have also shown that modulation of Ron, which is overexpressed in a variety of tumor types, has a dramatic effect on endothelial cell recruitment (Figure 5e ). Similar to a mouse model of breast cancer (Peace et al., 2005) , we have also shown a decrease in prostate tumor size correlating with decreased tumor microvessel density when Ron-deficient cells are orthotopically transplanted into prostates of nude mice (Figure 7) .
Mechanistically, our data show that Ron is an important regulator of NF-kB activity in DU145 and LNCaP cells. Knockdown of Ron in DU145 cells resulted in decreased NF-kB activity, and increased IkBa levels when compared with control cells. These findings correlate with the observed decreases in chemokine production and endothelial cell migration ( Figure 5 ). In addition, we also showed that the production of CXCL8 induced by Ron overexpression in LNCaP cells was blocked by treatment with a pharmacological inhibitor of NF-kB signaling (Figure 6d ). These data are consistent with published reports documenting the requirement of NF-kB signaling for the production of CXC ELR þ chemokines in PC-3 cells and suggest that Ron signaling has a positive effect on NF-kB regulation in prostate cancer cell lines (Shen and Lentsch, 2004) . þ /À 20-40 PZ-HPV-7 þ /À 20-40
Ron is highly expressed in PC-3 and DU145 prostate cancer cells when compared with CA-HPV-10, LNCaP, 22RV1 and PZ-HPV-7 prostate cells, as determined using western blot analysis and mean fluorescent intensity of Ron staining based on Flow cytometry.
In support of our studies with Ron and angiogenesis, the Met receptor has also been implicated in tumor angiogenesis. Interestingly, Met and Ron have similar expression patterns in prostate cancer cells (Figure 2a and Supplementary Figure S3A ). Treatment of small cell lung carcinoma cells and non-small cell lung carcinoma cells with the small molecule inhibitor for Met, PHA665752, in mouse xenograft experiments led to a reduction in tumor size and a dramatic reduction in tumor angiogenesis (Puri et al., 2007) . Similarly, Met activation by its ligand, hepatocyte growth factor (Bezerra et al., 1993) , has been shown to induce CXCL8 expression in esophageal squamous cell carcinoma cells and several reports have shown that serum levels of HGF are correlated with CXCL8 production (Ren et al., 2005) . These studies support the contention that the Ron receptor tyrosine kinase may have an important role in the production of angiogenic chemokines that promote tumor growth and angiogenesis. Therefore, targeting Ron may be useful therapeutically in a wide variety of cancers, including the treatment of prostate cancer, by affecting tumor angiogenesis.
Materials and methods
Immunohistochemistry on human prostate cancer specimens Immunohistochemistry was performed on tissue microarrays (Cat. no. IMH-303 Imgenex, San Diego, CA, USA; Cat. no. TMA1202-4, Chemicon/Millipore, Billerica, MA, USA; Cat. no. 75-4063, Zymed, Carlsbad, CA, USA) or from tissue samples obtained from the Cancer Center Tissue Bank of the University of Cincinnati. Tissue staining was performed as previously described (Peace et al., 2005) . Two antibodies were used for Ron immunohistochemistry, which provided similar results (1:50 Ron a, BD Transduction Laboratories, San Diego, CA, USA or 1:50 Ron C-20, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Samples with no primary antibody or an immunoglobulin G control antibody served as negative controls. Scoring the percentage of positive specimens for Ron and the mean intensity of Ron staining was performed as previously described (O'Toole et al., 2006) , with the mean intensity of epithelial staining obtained by multiplying the relative intensity score (0-3) by the percentage of epithelial cells staining positive for Ron.
Flow cytometry
Flow cytometric analyses were performed on prostate cells as follows: 1 Â 10 6 cells were fixed in 2% formaldehyde and resuspended in 1 ml 70% ethanol. Cell were permeabilized in phosphate buffered saline with bovine serum albumin and 0.5% Triton X-100, treated with primary antibody (1:100 Ron, C-20) or controls in phosphate buffered saline/bovine serum albumin/Triton X-100 for 1 h, and were subsequently incubated in phycoerythrin-conjugated anti-rabbit secondary antibody (0.5 mg, Molecular Probes, Carlsbad, CA, USA). After washing, cells were resuspended in 1 ml of water for flow analysis. The samples were analysed using a Coulter Epics XL (Beckman Coulter, Miami, FL, USA). Expression of Ron was graded as no detectable expression ( þ /À), low expression ( þ ), intermediate expression ( þ þ ) or high expression ( þ þ þ ) based on mean fluorescent intensity. A mean fluorescent intensity of o40 was considered no expression,
40-60 as low expression, 60-80 as intermediate expression and >80 as high Ron expression.
Quantitative real-time PCR RNA was isolated from the cell lines indicated and was used to generate complementary DNA using the High Capacity complementary DNA kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. To measure chemokine expression, quantitative real-time PCR analyses were performed using SYBR green incorporation (Applied Biosystems) with the following primers: CXCL8 forward: 5 0 -TTGGCAGCCTTCCTGATTTC-3 0 and reverse: 5 0 -TGAGAGTGATTGAGAGTGGACCA-3 0 ; Met (Yoshida et al., 2002) , VEGF 165 (Collado et al., 2007) and CXCL5 (Sawa et al., 2008) . Gene expression values were normalized to 18S forward: 5 0 -AGTCCCTGCCCTTTGTACACA-3 0 and reverse: 5 0 -GATCCGAGGGCCTCACTAAAC-3 0 as an internal control. Relative gene expression results are reported.
Immunoprecipitations, western blot analysis and kinase assays For immunoprecipitations, 1 mg of total cellular lysate in 1 ml of phosphate buffered saline containing protease inhibitor (Complete Mini, EDTA-free, Roche Diagnostics, Indianapolis, IN, USA) was incubated with 5 mg of primary antibody (Ron C-20, Santa Cruz Biotechnology) for 1 h at 4 1C. Protein G-agarose beads were added and complexes were incubated overnight at 4 1C. Immunocomplexes were then collected and subjected to western blot analysis as previously described (Zinser et al., 2006) . Primary antibodies used were Ron C-20 (1:400), phospho-Tyrosine (4G10 1:1000, Upstate, Billerica, CA, USA), phospho-Ron (Y1238/1239; 1 mg/ml, R&D Systems, Minneapolis, MN, USA), IkBa (1:500, Santa Cruz Biotechnology), Met (1:500, Santa Cruz Biotechnology) and Actin C4 (1:40 000; received as a gift from Dr James Lessard at Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA). Peroxidase-conjugated secondary antibodies were applied, membranes were developed using ECL Plus Western Blotting detection reagent (GE Healthcare, Piscataway, NJ, USA), and protein bands were detected using autoradiography. Kinase assays were performed as previously described (Zinser et al., 2006) with 1 mg of protein lysate used for immunoprecipitations with the Ron-a antibody and with myelin basic protein as the substrate. Samples were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the gels were fixed, dried and imaged on a phosphoimager (Typhoon Trio, GE Healthcare).
Chemokine production and enzyme-linked immunosorbent assay Cells were plated in a 24-well tissue culture dish in complete media. After reaching B80% confluency, serum-free media was added (Defined Keratinocyte Media, Gibco, Carlsbad, CA). Supernatants were collected over time and chemokine levels were determined using enzyme-linked immunosorbent assays according to the manufacturer's instructions (R&D Systems). Crystal violet assays were performed by fixing cells in 10% neutral buffered formalin for 15 min, and then incubating cells with 0.1% crystal violet in 25% methanol for 30 min. The cells were washed, air-dried and 500 ml of dimethylsulfoxide was added. After shaking 30 min, the absorbance was read at 570 nm. Relative cell number was plotted by calculating the fold change in cell growth from 0 to 72 h and normalizing the values to one cell line set at 1.0. The relative level of chemokine production between cell lines was calculated with the amount of chemokines produced normalized to the relative cell number observed during the time course of the experiment (Figures 3a and b) . All the LNCaP, 22RV1 and PC-3 cells grew to similar extents and the chemokine values were not adjusted. However, DU145 cells grew significantly faster during the experimental observation period (Figure 3d ) and the relative chemokine values for these cells were decreased accordingly by the change in cell number.
Nuclear factor-kB (NF-kB) activity To obtain cells with a stable knockdown of Ron, cells were infected with either a lentivirus or a retrovirus containing a Ron-specific shRNA or a nonsense shRNA as a control (constructs were purchased from Open Biosystems; Ron shRNA catalog no. RHS3979, RHS1764; viruses were prepared at the Cincinnati Children's Hospital viral vector core). Stable populations were then selected with 1 mg/ml puromycin. 1 Â 10 5 cells were plated in triplicate in minimum essential medium containing 5% fetal bovine serum. The next day, cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with either an NF-kB reporter (pNF-kBluc) or an empty vector (pTAL-luc) construct and a control plasmid expressing Renilla (pRL-TK). At 24 h after transfection, the cells were lysed and subjected to a dualluciferase assay according to manufacturer's protocol (Promega). Samples were read using the GloMax 96 Microplate Luminometer with Dual Injectors (Promega). NF-kB electrophoretic mobility shift assays were performed as previously described (Shen and Lentsch, 2004; Nikolaidis et al., 2009) .
Endothelial cell migration
Ron knockdown or control cells were plated in triplicate in minimum essential medium containing 5% fetal bovine serum. At 70% confluency, cells were serum starved, and 48 h later supernatant was collected and was used as the chemoattractant for endothelial cells (HUVECs) in a transwell migration assay. For the migration assay, 1 Â 10 5 HUVECs were plated in the top chamber of 8.0 mm transwells (Corning Costar Corporation, Cambridge, MA, USA) in endothelial cell growth media (Mediatech, Inc., Manassas, VA, USA). The following day, cells were washed with phosphate buffered saline, and serumfree minimum essential medium was added. For inhibition of CXCR2, 300 mM of SB225002 (Calbiochem, Gibbstown, NJ, USA) was added to HUVECs. The chemoattractant was diluted 1:10 in serum-free minimum essential medium, added to the bottom of the 24-well plate and HUVEC cells were allowed to migrate for 5 h. The number of live cells on the bottom of the transwell was measured using the 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide assay according to the manufacturer's instructions (Sigma-Aldrich, St Louis, MO, USA) with absorbance read at 570 nm.
Ron overexpression
LNCaP prostate cancer cells were transfected using Lipofectamine 2000 (Invitrogen) with a pCI-neo vector (Promega) containing human Ron complementary DNA or with pCI-neo as a control. Cells were selected with G418 and stable cells were plated at 3 Â 10 4 cells per well in six-well plates, grown to 70% confluency and serum starved for 24 h. Cells were treated with 100 ng/ml of recombinant HGFL (R&D Systems) in serum-free media or left untreated. A total of 50 mM of Bay 11-7082 (Calbiochem) was added to cells for 48 h to examine NF-kB inhibition. Supernatant was collected at 48 h and analysed using enzyme-linked immunosorbent assay.
Orthotopic injections and CD31 staining PC-3M-luc2 cells (5 Â 10 5 , Caliper Life Sciences, Hopkinton, MA, USA), a PC-3 cell line containing stable luciferase expression, or PC-3M-luc2 cells with a stable Ron knockdown, were orthotopically injected into dorsolateral prostates of 11-week-old nude mice. Tumors were harvested 7 weeks injection and tumor mass was recorded. The tumors were fixed and processed for histological analyses. CD31 staining was performed as previously described (Loh et al., 2009) . Tissues were incubated with an anti-CD31 antibody (1:500, Dako, CA, USA) and 3,3 0 -diaminobenzidine-enhanced liquid substrate system (3,3 0 -diaminobenzidine tetrahydrochloride-Sigma, MO, USA) was used for detection. Microvessel density was calculated as previously described (Peace et al., 2005) .
Statistical analysis
Data are expressed as mean±s.e. Statistical significance comparing different experimental groups was determined using Student's t-test for pairwise comparisons, or analysis of variance for comparison of multiple groups using SigmaPlot 11.0 (Systat Software, Inc., San Jose, CA, USA). Differences between groups were accepted as significant when Po0.05.
